{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:03:17Z","timestamp":1789646597122,"version":"4.0.0"},"reference-count":219,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbcan.2026.189711","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:22:35Z","timestamp":1789168955000},"page":"189711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanomedicine-based strategies to counter chemoresistance in diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"1881","author":[{"given":"Danyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189711_bb0010","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/cancers15030835","article-title":"The immunology of DLBCL","volume":"15","author":"Takahara","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/ijo.2026.5859","article-title":"Mechanisms of chemoresistance in diffuse large B-cell lymphoma and novel therapeutic strategies","volume":"68","author":"Wan","year":"2026","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70167","article-title":"TALOs, fill the gap: Tafasitamab and Lenalidomide in diffuse large B-cell lymphoma in the real-life patient journey","volume":"44","author":"Argnani","year":"2026","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71531","article-title":"Real-world outcomes of Polatuzumab Vedotin plus R-CHP versus R-CHOP-based regimens in Japanese patients with untreated diffuse large B-cell lymphoma","volume":"15","author":"Hotta","year":"2026","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2026.189711_bb0035","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2023-185065","article-title":"A phase Ib study to evaluate the safety and efficacy of Nivolumab in combination with R-CHOP in high-risk DLBCL","volume":"142","author":"Odetola","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0040","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.18900","article-title":"Genome-wide CRISPR screening uncovers potential targets and mechanisms of vincristine resistance in DLBCL","volume":"202","author":"He","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0045","first-page":"1","article-title":"CRISPR\/Cas9 in cancer therapy: precision genome editing approaches targeting hematological malignancies and solid tumors through cellular, biochemical, and molecular mechanisms","author":"Joshi","year":"2026","journal-title":"Cell Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70164","article-title":"Gemcitabine, carboplatin, dexamethasone, and rituximab versus high-dose Cytarabine-based chemotherapy as second-line treatments for relapsed or refractory diffuse large B-cell lymphoma","volume":"44","author":"Ikoma","year":"2026","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-026-06826-3","article-title":"Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study","volume":"105","author":"Lv","year":"2026","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0060","first-page":"1","article-title":"Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017\u20132024)","author":"Phillips","year":"2026","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0065","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/2643-3230.BCD-25-0059","article-title":"Golcadomide: an Oral CELMoD agent targeting IKZF1\/3 for diffuse large B-cell lymphoma","volume":"7","author":"Mo","year":"2026","journal-title":"Blood Cancer Discov."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0070","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/bloodadvances.2022008543","article-title":"Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL","volume":"7","author":"Torka","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjh.70228","article-title":"Bispecific antibody combination therapies in diffuse large B-cell lymphoma","volume":"208","author":"Harrop","year":"2026","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0080","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00277-024-06134-8","article-title":"Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: in vitro evaluation","volume":"104","author":"Ahmed","year":"2025","journal-title":"Ann. Hematol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0085","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.62347\/XWSP9750","article-title":"Optimization of CAR-T therapy based on metabolic remodeling of the tumor immune microenvironment in diffuse large B-cell lymphoma","volume":"15","author":"Yuan","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189711_bb0090","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12935-025-03879-8","article-title":"Amino acid-based risk stratification model improves prognostic precision in diffuse large B-cell lymphoma","volume":"25","author":"Zhang","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0100","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/biomedicines13030707","article-title":"Fatty acid metabolism provides an essential survival signal in OxPhos and BCR DLBCL cells","volume":"13","author":"Montagne","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2026.189711_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.118975","article-title":"High leptin levels independent of body mass index are associated with inflammation and poorer treatment response in patients with diffuse large B-cell lymphoma","volume":"195","author":"Hontecillas-Prieto","year":"2026","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13402-025-01142-w","article-title":"Ferroptosis in hematological malignancies: molecular mechanisms and therapeutic potential","volume":"49","author":"Liu","year":"2026","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.149077","article-title":"Identification of oxidative stress-related hub genes for predicting prognosis in diffuse large B-cell lymphoma","volume":"935","author":"Zhao","year":"2025","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0120","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1007\/s12668-024-01445-6","article-title":"Unleashing the potential of ibrutinib-loaded nanoparticles for cancer treatment \u2014 a comprehensive review","volume":"14","author":"Behzadmehr","year":"2024","journal-title":"BioNanoScience"},{"key":"10.1016\/j.bbcan.2026.189711_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125294","article-title":"Nucleolin-targeted silicon-based nanoparticles for enhanced chemo-sonodynamic therapy of diffuse large B-cell lymphoma","volume":"671","author":"Wang","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41420-025-02826-w","article-title":"Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL)","volume":"11","author":"Langpape","year":"2025","journal-title":"Cell Death Discov."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189711_bb0135","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/diagnostics11101739","article-title":"Dysregulation of miRNAs in DLBCL: causative factor for pathogenesis, diagnosis and prognosis","volume":"11","author":"Alsaadi","year":"2021","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0140","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/ncrna12010002","article-title":"The role of microRNAs as potential biomarkers in diffuse large B-cell lymphoma","volume":"12","author":"Panteli","year":"2026","journal-title":"Non-Coding RNA"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0145","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/cancers17081300","article-title":"MicroRNAs in diffuse large B-cell lymphoma (DLBCL): biomarkers with prognostic potential","volume":"17","author":"Veryaskina","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189711_bb0150","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S587953","article-title":"Advances in nanotechnology for lymphoma treatment: targeted delivery, immunomodulation, and TME-responsive therapy strategies","volume":"21","author":"Han","year":"2026","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2026.189711_bb0155","article-title":"CD20 targeted nanomedicine for GCB-diffuse large B-cell lymphoma through synergistic effects of apoptosis and ferroptosis","volume":"32","author":"Liu","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.bbcan.2026.189711_bb0160","first-page":"176","article-title":"Combination of daratumumab and doxorubicin loaded polycaprolactone nanoparticles in the treatment of diffuse large B-cell lymphoma","volume":"29","author":"Erdogar","year":"2022","journal-title":"Ann. Med. Res."},{"key":"10.1016\/j.bbcan.2026.189711_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1069378","article-title":"The immune checkpoint expression in the tumor immune microenvironment of DLBCL: clinicopathologic features and prognosis","volume":"12","author":"Ma","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1591759","article-title":"Clinical efficacy and safety of umbralisib, a dual PI3K\u03b4\/CK1-\u03f5 inhibitor, in treatment of hematologic malignancies","volume":"15","author":"Zang","year":"2026","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0175","first-page":"1973","article-title":"The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment","volume":"6","author":"Yang","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bbcan.2026.189711_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.947823","article-title":"A bone-based 3D scaffold as an in-vitro model of microenvironment\u2013DLBCL lymphoma cell interaction","volume":"12","author":"Ceccato","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-025-01326-5","article-title":"Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma","volume":"15","author":"Walker","year":"2025","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0190","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/13813455.2024.2404099","article-title":"MiR-93 promotes the progression and chemoresistance of diffuse large B-cell lymphoma cells via targeting SMAD5","volume":"131","author":"Fang","year":"2025","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.bbcan.2026.189711_bb0195","first-page":"245","article-title":"Drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory DLBCL","author":"Zhang","year":"2023","journal-title":"Cancer Manag. Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/kjm2.70158","article-title":"Fat mass and obesity-associated protein contributes to tumorigenesis and drug resistance of diffuse large B-cell lymphoma by suppressing N6-Methyladenosine methylation of Myc","volume":"42","author":"Lu","year":"2026","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0205","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/cas.15402","article-title":"CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a\/b to disinhibit PD-L1","volume":"113","author":"Dong","year":"2022","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189711_bb0210","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.2023021142","article-title":"Chemoresistance pathways in DLBCL","volume":"142","author":"Deaglio","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0215","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-024-01080-0","article-title":"Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL","volume":"14","author":"Wenzl","year":"2024","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb0220","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11523-023-00983-5","article-title":"Molecularly stratified treatment options in primary refractory DLBCL\/HGBL with MYC and BCL2 or BCL6 rearrangements (HGBL, NOS with MYC\/BCL6)","volume":"18","author":"Witte","year":"2023","journal-title":"Target. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189711_bb0225","doi-asserted-by":"crossref","DOI":"10.26599\/NR.2025.94908016","article-title":"E5 peptide-functionalized platinum nanozymes mediate immune microenvironment reprogramming in B-cell lymphoma","volume":"18","author":"Wang","year":"2025","journal-title":"Nano Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-022-04407-5","article-title":"Hsp90 inhibition sensitizes DLBCL cells to cisplatin","volume":"89","author":"Schmidt","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189711_bb0235","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.7150\/jca.85906","article-title":"FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance","volume":"14","author":"Chen","year":"2023","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0240","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/ijmm.2024.5448","article-title":"TP53 mutations in cancer: molecular features and therapeutic opportunities","volume":"55","author":"Tornesello","year":"2024","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0245","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41419-025-07843-2","article-title":"Heat shock factor 1 promotes proliferation and chemoresistance in diffuse large B-cell lymphoma by enhancing the cell cycle and DNA repair","volume":"16","author":"Fang","year":"2025","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0250","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/bloodadvances.2022007825","article-title":"Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL","volume":"7","author":"Mazzara","year":"2023","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2024.8746","article-title":"Advances in proteomics in diffuse large B-cell lymphoma","volume":"51","author":"Guo","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189711_bb0260","article-title":"Regulation and therapy: the role of ferroptosis in DLBCL","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101243","article-title":"Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibition","volume":"70","author":"Niccolai","year":"2025","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb0270","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0275","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-21-0216","article-title":"Acquired resistance to EZH2 inhibitor GSK343 promotes the differentiation of human DLBCL cell lines toward an ABC-like phenotype","volume":"21","author":"Preston","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb0280","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1007\/s10895-024-04092-y","article-title":"Thermo-responsive fluorescent nanopolymer delivery platform for treatment of diffuse large B-cell lymphoma (DLBCL)","volume":"35","author":"Lin","year":"2025","journal-title":"J. Fluoresc."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0285","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.62347\/IMFU7145","article-title":"USP13 mediates resistance to Ibrutinib in diffuse large B-cell lymphoma via augmenting FHL1 stabilization","volume":"15","author":"Tao","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189711_bb0290","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood.2022018752","article-title":"DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0295","article-title":"Constitutive NF-\u03baB activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma","volume":"2015","author":"Turturro","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0300","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/PAS.0000000000000396","article-title":"Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR\/PI3K\/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features","volume":"39","author":"Wang","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0305","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2017.5","article-title":"NF-\u03baB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53","volume":"30","author":"Cai","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fonc.2019.00107","article-title":"Dysregulation of cell survival in diffuse large B cell lymphoma: mechanisms and therapeutic targets","volume":"9","author":"Miao","year":"2019","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0315","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ccr.2012.11.003","article-title":"MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo","volume":"22","author":"Fontan","year":"2012","journal-title":"Cancer Cell"},{"issue":"7277","key":"10.1016\/j.bbcan.2026.189711_bb0320","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-023-00809-7","article-title":"MALT1-dependent cleavage of CYLD promotes NF-\u03baB signaling and growth of aggressive B-cell receptor-dependent lymphomas","volume":"13","author":"Minderman","year":"2023","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0330","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0335","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/ijms19061758","article-title":"Molecular mechanisms of disease progression in primary cutaneous diffuse large B-cell lymphoma, leg type during ibrutinib therapy","volume":"19","author":"Fox","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.bbcan.2026.189711_bb0340","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTKCys481Ser drives ibrutinib resistance via ERK1\/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189711_bb0345","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1073\/pnas.1921187117","article-title":"Regulation of B cell receptor-dependent NF-\u03baB signaling by the tumor suppressor KLHL14","volume":"117","author":"Choi","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0350","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/2643-3230.BCD-21-0131","article-title":"Epigenetic rewiring of BCR signaling as a novel mechanism of ibrutinib resistance in ABC-DLBCL","volume":"2","author":"Pasqualucci","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"18","key":"10.1016\/j.bbcan.2026.189711_bb0355","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/bloodadvances.2020001685","article-title":"Targeting phosphatidylinositol 3 kinase-\u03b2 and-\u03b4 for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0360","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3109\/10428191003802365","article-title":"Leptin receptor expression and its association with PI3K\/AKT signaling pathway in diffuse large B-cell lymphoma","volume":"51","author":"Uddin","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"30","key":"10.1016\/j.bbcan.2026.189711_bb0365","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0370","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.neo.2018.03.002","article-title":"Clinical significance of PTEN deletion, mutation, and loss of PTEN expression in de novo diffuse large B-cell lymphoma","volume":"20","author":"Wang","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2026.189711_bb0375","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.2147\/OTT.S247429","article-title":"Targeting PIN-1 attenuates GCB DLBCL cell proliferation through inhibition of PI3K\/AKT signaling","author":"Yang","year":"2020","journal-title":"Onco. Targets Ther."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189711_bb0380","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz9798","article-title":"Pretargeted delivery of PI3K\/mTOR small-molecule inhibitor\u2013loaded nanoparticles for treatment of non-Hodgkin\u2019s lymphoma","volume":"6","author":"Au","year":"2020","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0385","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1158\/1078-0432.CCR-10-0720","article-title":"Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K\/Akt\/NF-\u03baB pathway in human non\u2013small cell lung cancer","volume":"17","author":"Song","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189711_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113361","article-title":"Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K\/AKT\/PD-L1 axis","volume":"143","author":"Liu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153620","article-title":"Sphk1 promotes salivary adenoid cystic carcinoma progression via PI3K\/Akt signaling","volume":"227","author":"Hou","year":"2021","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb0400","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.leukres.2008.06.010","article-title":"PI3K\/Akt inhibition modulates multidrug resistance and activates NF-\u03baB in murine lymphoma cell lines","volume":"33","author":"Garc\u00eda","year":"2009","journal-title":"Leuk. Res."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189711_bb0405","first-page":"2926","article-title":"Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2","volume":"114","author":"Gupta","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189711_bb0410","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0960-9822(99)80265-6","article-title":"Induction of NF-\u03baB by the Akt\/PKB kinase","volume":"9","author":"Kane","year":"1999","journal-title":"Curr. Biol."},{"issue":"31","key":"10.1016\/j.bbcan.2026.189711_bb0415","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non\u2013mantle cell non-Hodgkin\u2019s lymphoma subtypes: the University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0420","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/hon.2662","article-title":"A phase II study to assess the safety and efficacy of the dual mTORC1\/2 inhibitor vistusertib in relapsed, refractory DLBCL","volume":"37","author":"Eyre","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112333","article-title":"Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma","volume":"28","author":"Rossi","year":"2025","journal-title":"Iscience"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104104","article-title":"Epstein-Barr Virus\u2013Encoded Latent Membrane Protein 2A promotes immune escape by upregulating SYK\/Nuclear factor-\u03baB signaling in diffuse large B-cell Lymphoma","volume":"105","author":"Jiang","year":"2025","journal-title":"Lab. Investig."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb0435","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/CAD.0000000000001696","article-title":"BTK inhibitors enhance NKG2D ligand expression by regulating IL-10\/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells","volume":"36","author":"Jia","year":"2025","journal-title":"Anti-Cancer Drugs"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb0440","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jcp.10364","article-title":"STAT proteins: from normal control of cellular events to tumorigenesis","volume":"197","author":"Cal\u00f2","year":"2003","journal-title":"J. Cell. Physiol."},{"issue":"36","key":"10.1016\/j.bbcan.2026.189711_bb0445","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2012.45.6004","article-title":"Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP","volume":"31","author":"Huang","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0450","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1158\/1078-0432.CCR-08-1588","article-title":"Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy","volume":"15","author":"Park","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189711_bb0455","article-title":"Prognostic genes related to mitochondrial dynamics and mitophagy in diffuse large B-cell lymphoma are identified and validated using an integrated analysis of bulk and single-cell RNA sequencing","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0460","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0465","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/leu.2015.57","article-title":"IL10 receptor is a novel therapeutic target in DLBCLs","volume":"29","author":"B\u00e9guelin","year":"2015","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189711_bb0470","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1158\/1078-0432.CCR-22-2483","article-title":"Phase I study of acalabrutinib plus danvatirsen (AZD9150) in relapsed\/refractory diffuse large B-cell lymphoma including circulating tumor DNA biomarker assessment","volume":"29","author":"Roschewski","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0475","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/10428194.2025.2568186","article-title":"MiR-22-3p regulates the SIRT1\/P53 signaling pathway, thereby influencing ferroptosis in diffuse large B-cell lymphoma cells","volume":"67","author":"Lu","year":"2026","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb0480","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41375-026-02948-9","article-title":"Targeting of ibrutinib resistance\u2013driving pathways by miR-28 in ABC-DLBCL","volume":"40","author":"\u00c1lvarez-Corrales","year":"2026","journal-title":"Leukemia"},{"issue":"Pt 2","key":"10.1016\/j.bbcan.2026.189711_bb0485","first-page":"149748","article-title":"Silencing of lncRNA HOTAIR enhances doxorubicin sensitivity and induces apoptosis in diffuse large B-cell lymphoma cells","volume":"338","author":"Rajabi","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0490","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ejmech.2018.10.001","article-title":"The use of proteomic technologies to study molecular mechanisms of multidrug resistance in cancer","volume":"162","author":"Cao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189711_bb0495","doi-asserted-by":"crossref","first-page":"14655","DOI":"10.1021\/acs.jmedchem.2c01175","article-title":"New dual P-glycoprotein (P-gp) and human carbonic anhydrase XII (hCA XII) inhibitors as multidrug resistance (MDR) reversers in cancer cells","volume":"65","author":"Braconi","year":"2022","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189711_bb0500","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.3390\/cancers15174236","article-title":"Genetics of ABCB1 in cancer","volume":"15","author":"Skinner","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189711_bb0505","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.3390\/ijms26104701","article-title":"P-glycoprotein as a therapeutic target in hematological malignancies: a challenge to overcome","volume":"26","author":"\u00c1lvarez-Carrasco","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"47","key":"10.1016\/j.bbcan.2026.189711_bb0510","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0515","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/14622416.2.1.51","article-title":"ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2","volume":"2","author":"Kerb","year":"2001","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189711_bb0520","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/modpathol.2009.98","article-title":"Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma","volume":"22","author":"Kim","year":"2009","journal-title":"Mod. Pathol."},{"issue":"4\u20136","key":"10.1016\/j.bbcan.2026.189711_bb0525","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000086984","article-title":"Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma","volume":"68","author":"Ohsawa","year":"2005","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202500105","article-title":"Metabolism-regulating nanomedicines for cancer therapy","volume":"6","author":"Wu","year":"2026","journal-title":"Adv. Nanobiomed. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70174","article-title":"Integrating multi-omics features enables non-invasive early diagnosis and treatment response prediction of diffuse large B-cell lymphoma","volume":"15","author":"Zhang","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0540","first-page":"545","article-title":"The metabolic role of lactate dehydrogenase in the growth of diffuse large B cell lymphoma","volume":"104","author":"Zhang","year":"2025","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb0545","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.62347\/LAQY2536","article-title":"Enhanced glycolysis induced by activation of AKT\/NF-\u03baB signaling pathway contributes to doxorubicin resistance in DLBCL","volume":"15","author":"Wu","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb0550","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41375-022-01769-w","article-title":"Sustained activation of non-canonical NF-\u03baB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL","volume":"37","author":"Lim","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0555","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers17030394","article-title":"Metabolic heterogeneity in diffuse large B-cell lymphoma cells reveals an innovative antimetabolic combination strategy","volume":"17","author":"Lordello","year":"2025","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.bbcan.2026.189711_bb0560","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1182\/bloodadvances.2023010964","article-title":"Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress","volume":"7","author":"Gomez Solsona","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb0565","first-page":"452","article-title":"A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc\/Bcl-2\/Mcl-1 triple targeting","volume":"13","author":"Jeon","year":"2023","journal-title":"Am. J. Cancer Res."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189711_bb0570","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood.2020008017","article-title":"Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition","volume":"137","author":"Bala Tannan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189711_bb0575","first-page":"45","article-title":"Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity","volume":"7","author":"Cioce","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bbcan.2026.189711_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1435480","article-title":"Lipids in the tumor microenvironment: immune modulation and metastasis","volume":"14","author":"Pascual","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1585521","article-title":"Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target","volume":"13","author":"Zhou","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0590","article-title":"Prognostic role of tumor microenvironment in DLBCL and relation to patients\u2019 clinical outcome: a clinical and immunohistochemical study","volume":"2022","author":"Ghorab","year":"2022","journal-title":"Anal. Cell. Pathol."},{"issue":"244","key":"10.1016\/j.bbcan.2026.189711_bb0595","first-page":"197","article-title":"The expression and significance of CXCL13 and CXCR5 in the tumor microenvironment of primary central nervous system diffuse large B-cell lymphoma","volume":"16","author":"Li","year":"2025","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0600","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2141.2011.08794.x","article-title":"Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin \u03b1-4-\u03b2-1 (VLA-4) with natalizumab can overcome this resistance","volume":"155","author":"Mraz","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb0605","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/10245332.2017.1312205","article-title":"Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in non-Hodgkin\u2019s lymphoma","volume":"22","author":"Yin","year":"2017","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0610","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/sj.leu.2404723","article-title":"Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-\u03baB (RelB\/p52) in non-Hodgkin\u2019s lymphoma cells","volume":"21","author":"Lwin","year":"2007","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bbcan.2026.189711_bb0615","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2010-03-275925","article-title":"Follicular dendritic cell\u2013dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion\u2013mediated Bim down-regulation through induction of microRNA-181a","volume":"116","author":"Lwin","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189711_bb0620","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1172\/JCI64210","article-title":"A microenvironment-mediated c-Myc\/miR-548m\/HDAC6 amplification loop in non-Hodgkin B cell lymphomas","volume":"123","author":"Lwin","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0625","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2141.2008.07037.x","article-title":"Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma","volume":"141","author":"Linderoth","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0630","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1186\/s12885-025-14737-1","article-title":"Identification of the IFN-\u03b3\/IL-4 ratio as a prognostic biomarker and development of an immune-related prognostic model in diffuse large B-cell lymphoma","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0635","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/biomedicines13040853","article-title":"Epigenetic symphony in diffuse large B-cell lymphoma: orchestrating the tumor microenvironment","volume":"13","author":"Caloian","year":"2025","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb0640","doi-asserted-by":"crossref","DOI":"10.25122\/jml-2025-0078","article-title":"PD-L1 expression and tumor microenvironment dynamics in diffuse large B-cell lymphoma: immunophenotypic insights","volume":"18","author":"Halcu","year":"2025","journal-title":"J. Med. Life"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0645","article-title":"Efficacy and safety of anti-PD-1\/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: a meta-analysis","volume":"20","author":"Zhang","year":"2025","journal-title":"Open Life Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0650","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189711_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2025.102042","article-title":"RCN1 affects malignant progression and macrophage M2 polarization in diffuse large B-cell lymphoma","volume":"83","author":"Zhu","year":"2025","journal-title":"Mol. Cell. Probes"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189711_bb0660","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1097\/MS9.0000000000001162","article-title":"The expression of hypoxia inducible factor-1 alpha in diffuse large B-cell lymphoma (DLBCL) patients: a cross-sectional study in Indonesia","volume":"85","author":"Pangarsa","year":"2023","journal-title":"Ann. Med. Surg."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb0665","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s12013-024-01637-7","article-title":"A novel hypoxia-featured genes prognostic model for identification of hypoxia subtypes in diffuse large B-cell lymphoma","volume":"83","author":"Lyu","year":"2025","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.bbcan.2026.189711_bb0670","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.omto.2023.08.009","article-title":"Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL","volume":"30","author":"Zhou","year":"2023","journal-title":"Mol. Ther. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0675","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3390\/ijms27041737","article-title":"In vivo CAR-T therapies \u2014 a new era of programmable immunity","volume":"27","author":"Pierini","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189711_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114988","article-title":"Zinc oxide nanoparticles induce toxicity in diffuse large B-cell lymphoma cell line U2932 via activating PINK1\/Parkin-mediated mitophagy","volume":"164","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0685","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.nano.2015.04.015","article-title":"Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases","volume":"11","author":"Jo","year":"2015","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189711_bb0690","first-page":"444","article-title":"Size, shape, charge and \u201cstealthy\u201d surface: carrier properties affect the drug circulation time in vivo","volume":"16","author":"Di","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.bbcan.2026.189711_bb0695","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2024.1456939","article-title":"Recent advances in surface decoration of nanoparticles in drug delivery","volume":"6","author":"Ly","year":"2024","journal-title":"Front. Nanotechnol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121607","article-title":"Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC\/BCL6-positive double-hit diffuse large B-cell lymphoma","volume":"287","author":"Yang","year":"2022","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189711_bb0705","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1021\/acs.molpharmaceut.7b00710","article-title":"Rational targeting of cellular cholesterol in diffuse large B-cell lymphoma (DLBCL) enabled by functional lipoprotein nanoparticles: a therapeutic strategy dependent on cell of origin","volume":"14","author":"Rink","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2026.189711_bb0710","series-title":"Investigations of Redox Resistance in Aggressive Lymphomas with Cholesterol Modulating Lipid Nanoparticles","author":"Yang","year":"2022"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0715","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/gels11030218","article-title":"Injectable magnetic-nanozyme based thermosensitive hydrogel for multimodal DLBCL therapy","volume":"11","author":"Yan","year":"2025","journal-title":"Gels"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0720","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/cancers14030626","article-title":"Targeted drug delivery and theranostic strategies in malignant lymphomas","volume":"14","author":"Etrych","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0725","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","author":"Attia","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb0730","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/pharmaceutics15092233","article-title":"Recent advances in targeted drug delivery strategy for enhancing oncotherapy","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0735","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.7150\/thno.106758","article-title":"CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies","volume":"15","author":"Qin","year":"2025","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0740","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/0008-5472.CAN-20-2674","article-title":"Optimized doxorubicin chemotherapy for diffuse large B-cell lymphoma exploits nanocarrier delivery to transferrin receptors","volume":"81","author":"Arumov","year":"2021","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189711_bb0745","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.3390\/molecules27217143","article-title":"Synthesis and biological evaluation of PEGylated MWO4 nanoparticles as sonodynamic AID inhibitors in treating diffuse large B-cell lymphoma","volume":"27","author":"Jiao","year":"2022","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb0750","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1021\/acs.jmedchem.5c02897","article-title":"A ROS-responsive dimeric prodrug nanoassembly for amplified epigenetic therapy of lymphoma","volume":"69","author":"Li","year":"2026","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0755","doi-asserted-by":"crossref","first-page":"524","DOI":"10.7150\/jca.126813","article-title":"A comprehensive review of nanotechnological innovations in cancer: from molecular pathways to clinical applications","volume":"17","author":"Nawaz","year":"2026","journal-title":"J. Cancer"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189711_bb0760","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/cells14171334","article-title":"Doxorubicin-loaded nanoparticle treatment enhances diffuse large B-cell lymphoma cell death","volume":"14","author":"Abd-Elrahman","year":"2025","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189711_bb0765","doi-asserted-by":"crossref","first-page":"9253","DOI":"10.3390\/ijms25179253","article-title":"Nanotechnology advances in the detection and treatment of lymphoid malignancies","volume":"25","author":"Adamo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"48","key":"10.1016\/j.bbcan.2026.189711_bb0770","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1039\/c3tb21238f","article-title":"Liposome-like nanostructures for drug delivery","volume":"1","author":"Gao","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bbcan.2026.189711_bb0775","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.2147\/IJN.S520567","article-title":"Macrophage membrane-coated liposomes delivering vonoprazan disrupt mitochondrial oxidative phosphorylation in diffuse large B-cell lymphoma","author":"Wang","year":"2025","journal-title":"Int. J. Nanomedicine"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189711_bb0780","doi-asserted-by":"crossref","DOI":"10.1149\/1945-7111\/ae0bb6","article-title":"Polymer\u2013silica hybrid hydrogels with electrochemical characteristics and inhibit diffuse large B-cell lymphoma progression","volume":"172","author":"Yang","year":"2025","journal-title":"J. Electrochem. Soc."},{"key":"10.1016\/j.bbcan.2026.189711_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119176","article-title":"Noble metal\/dextran-graft-polyacrylamide branched polymer nanocomposites induce ROS-dependent apoptosis in diffuse large B-cell lymphoma cells","volume":"197","author":"Tkachenko","year":"2026","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189711_bb0790","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.7150\/thno.43231","article-title":"Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model","volume":"10","author":"Falg\u00e0s","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189711_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112940","article-title":"A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice","volume":"150","author":"Falgas","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189711_bb0800","article-title":"Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL","volume":"35","author":"Sun","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0805","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1021\/acs.biomac.1c01497","article-title":"Surface-functionalized polymeric siRNA nanoparticles for tunable targeting and intracellular delivery to hematologic cancer cells","volume":"23","author":"Kwak","year":"2022","journal-title":"Biomacromolecules"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189711_bb0810","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1016\/j.biomaterials.2012.01.027","article-title":"Simultaneous gene transduction and silencing using stimuli-responsive viral\/nonviral chimeric nanoparticles","volume":"33","author":"Cho","year":"2012","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb0815","first-page":"498","article-title":"Iron oxide nanoparticles inhibit tumor growth by ferroptosis in diffuse large B-cell lymphoma","volume":"13","author":"Huang","year":"2023","journal-title":"Am. J. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb0820","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1039\/C5CS00699F","article-title":"In vivo degeneration and the fate of inorganic nanoparticles","volume":"45","author":"Feliu","year":"2016","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0825","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3390\/ijms27031495","article-title":"Unlocking the secrets of regulated cell death in large B-cell lymphoma beyond apoptosis: signaling pathways and therapeutic options","volume":"27","author":"Tkachenko","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189711_bb0830","series-title":"Nanostructured Polymers: Synthesis and Performance","first-page":"377","article-title":"Nanopolymers applications in medical imaging, diagnostics, drug delivery, cell activity regulation, sensors and therapy","author":"Rajput","year":"2026"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0835","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1039\/c2nr32880a","article-title":"Lipid-enveloped hybrid nanoparticles for drug delivery","volume":"5","author":"Tan","year":"2013","journal-title":"Nanoscale"},{"issue":"18","key":"10.1016\/j.bbcan.2026.189711_bb0840","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1021\/acs.langmuir.6b00493","article-title":"Interfacing zwitterionic liposomes with inorganic nanomaterials: surface forces, membrane integrity, and applications","volume":"32","author":"Liu","year":"2016","journal-title":"Langmuir"},{"issue":"8_Supplement_1","key":"10.1016\/j.bbcan.2026.189711_bb0845","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1538-7445.AM2025-4485","article-title":"Resistance to ferroptosis in high grade diffuse large B-cell lymphoma is mediated through the Nrf2 signaling pathway","volume":"85","author":"Yang","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189711_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2026.115416","article-title":"Esterase-activatable dimeric HDAC inhibitor nanotherapeutics for enhanced lymphoma epigenetic therapy","volume":"261","author":"Li","year":"2026","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0855","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-024-02057-0","article-title":"Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the \u201cSmart\u201d exosome nanoparticle therapy","volume":"23","author":"Wu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0860","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1021\/acs.bioconjchem.2c00529","article-title":"Cell-penetrating peptide conjugated Au nanoclusters selectively suppress refractory lymphoma cells via targeting both canonical and noncanonical NF-\u03baB signaling pathways","volume":"34","author":"Lai","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bbcan.2026.189711_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.nxnano.2026.100387","article-title":"Emerging smart nanocarrier based drug delivery systems for cancer therapeutics","volume":"9","author":"Alam","year":"2026","journal-title":"Next Nanotechnol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189711_bb0870","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1248\/cpb.c20-00008","article-title":"Co-delivery systems of multiple drugs using nanotechnology for future cancer therapy","volume":"68","author":"Fumoto","year":"2020","journal-title":"Chem. Pharm. Bull."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0875","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.3390\/ijms26083820","article-title":"Co-encapsulation of multiple antineoplastic agents in liposomes by exploring microfluidics","volume":"26","author":"Asghar","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189711_bb0880","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509322","article-title":"DNA-loaded targeted nanoparticles as a safe platform to produce exogenous proteins in tumor B cells","volume":"15","author":"Grimaldi","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0885","doi-asserted-by":"crossref","first-page":"22312","DOI":"10.1038\/srep22312","article-title":"CRISPR\/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo","volume":"6","author":"Chang","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0890","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1373\/clinchem.2011.181016","article-title":"MicroRNAs regulate expression of oncogenes","volume":"59","author":"Slack","year":"2013","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-907X-3-1","article-title":"Inhibition of microRNA function by antimiR oligonucleotides","volume":"3","author":"Stenvang","year":"2012","journal-title":"Silence"},{"key":"10.1016\/j.bbcan.2026.189711_bb0900","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jconrel.2020.08.026","article-title":"Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles","volume":"327","author":"Malik","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0905","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41698-025-01049-7","article-title":"Exosome-transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA\/Hippo axis","volume":"9","author":"Liu","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0910","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/cancers15010235","article-title":"In vitro diffuse large B-cell lymphoma cell line models as tools to investigate novel immunotherapeutic strategies","volume":"15","author":"Kubacz","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189711_bb0915","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2147\/IJN.S355408","article-title":"Transcriptomics-based investigation of molecular mechanisms underlying apoptosis induced by ZnO nanoparticles in human diffuse large B-cell lymphoma","author":"Alsagaby","year":"2022","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0920","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12967-024-06028-3","article-title":"Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed\/refractory diffuse large B-cell lymphoma","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb0925","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2174\/1389557523666230915103121","article-title":"Recent advances in Nanobiotechnology for the treatment of non-Hodgkin\u2019s lymphoma","volume":"24","author":"Liu","year":"2024","journal-title":"Mini-Rev. Med. Chem."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189711_bb0930","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.3390\/ijms23147874","article-title":"Distinct chemokine receptor expression profiles in de novo DLBCL, transformed follicular lymphoma, Richter\u2019s transformed DLBCL and germinal center B-cells","volume":"23","author":"Uhl","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189711_bb0935","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.exphem.2022.09.005","article-title":"Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12","volume":"116","author":"Nagao","year":"2022","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbcan.2026.189711_bb0940","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fonc.2020.00351","article-title":"The tumor microenvironment of DLBCL in the computational era","volume":"10","author":"Opinto","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb0945","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41598-018-19182-8","article-title":"Role of hypoxia in diffuse large B-cell lymphoma: metabolic repression and selective translation of HK2 facilitates development of DLBCL","volume":"8","author":"Bhalla","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189711_bb0950","doi-asserted-by":"crossref","first-page":"12217","DOI":"10.2147\/IJN.S548088","article-title":"Current advances in nanocarriers for cancer therapy","author":"Zeinali","year":"2025","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb0955","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5045\/br.2022.2021145","article-title":"Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8+ T-cells despite immune checkpoint signaling","volume":"57","author":"Greenbaum","year":"2022","journal-title":"Blood Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb0960","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1007\/s00277-025-06530-8","article-title":"Efficacy of radiotherapy in primary mediastinal diffuse large B-cell lymphoma: a systematic review and meta-analysis of 1,392 patients","volume":"104","author":"Zhuang","year":"2025","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb0965","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/10428194.2021.2023742","article-title":"Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation","volume":"63","author":"Ge","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb0970","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pro6.1071","article-title":"Role of radiotherapy in diffuse large B-cell lymphoma in advanced stages on complete response after administration of cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab","volume":"3","author":"Aviles","year":"2019","journal-title":"Precision Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb0975","article-title":"Radioisotope-labeled nanomedicines for cancer therapy: recent advances, synergistic strategies, and future challenges","volume":"9","author":"Luo","year":"2026","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189711_bb0980","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1166\/jnn.2015.10617","article-title":"Applications of nanomaterials in radiotherapy for malignant tumors","volume":"15","author":"Wang","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"issue":"15_Supplement","key":"10.1016\/j.bbcan.2026.189711_bb0985","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1158\/1538-7445.AM2015-3102","article-title":"AZD1152HQPA Accurin\u2122 nanoparticles inhibit growth of diffuse large B-cell lymphomas and small cell lung cancer","volume":"75","author":"Ashton","year":"2015","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189711_bb0990","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1182\/bloodadvances.2017005892","article-title":"Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment","volume":"1","author":"Burack","year":"2017","journal-title":"Blood Adv."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189711_bb0995","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V126.23.817.817","article-title":"Diffuse large B-cell lymphoma patient-derived xenograft models capture molecular and biologic heterogeneity and inform therapy","volume":"126","author":"Chapuy","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb1000","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41374-022-00784-w","article-title":"Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas","volume":"102","author":"Jak\u0161a","year":"2022","journal-title":"Lab. Investig."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb1005","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.7150\/jca.68453","article-title":"Global research trends on the treatment of diffuse large B-cell lymphoma: a bibliometric and visualized study","volume":"13","author":"Duan","year":"2022","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb1010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13148-016-0245-y","article-title":"Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients","volume":"8","author":"Pera","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbcan.2026.189711_bb1015","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/OTT.S326632","article-title":"Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options","volume":"15","author":"Vodicka","year":"2022","journal-title":"Onco. Targets Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb1020","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-18-0577","article-title":"Modeling dose and schedule effects of AZD2811 nanoparticles targeting aurora B kinase for treatment of diffuse large B-cell lymphoma","volume":"18","author":"Floc\u2019h","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189711_bb1025","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood-2023-175014","article-title":"A first in human phase I trial (LS1681) of Abraxane\/rituximab 160 nm nanoparticle (AR160) in relapsed refractory B-cell lymphomas including transformed follicular lymphoma: a final report","volume":"142","author":"Habermann","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189711_bb1030","series-title":"A Phase 2 Study of PNT2258 in Patients with Relapsed or Refractory (r\/r) Diffuse Large b-Cell Lymphoma (DLBCL): An Initial Report from the Wolverine Study","author":"Westin","year":"2016"},{"key":"10.1016\/j.bbcan.2026.189711_bb1035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1693730","article-title":"CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma","volume":"16","author":"Rodr\u00edguez","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189711_bb1040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.23736\/S0026-4806.19.06236-0","article-title":"Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin+\/\u2212rituximab in treating diffuse large B-cell lymphoma","volume":"112","author":"Gao","year":"2021","journal-title":"Minerva Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb1045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2014.09.001","article-title":"Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial","volume":"15","author":"Oki","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189711_bb1050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-014-2476-y","article-title":"Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide","volume":"74","author":"Rodrigueza","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"27","key":"10.1016\/j.bbcan.2026.189711_bb1055","doi-asserted-by":"crossref","first-page":"42374","DOI":"10.18632\/oncotarget.9872","article-title":"PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin\u2019s lymphoma","volume":"7","author":"Ebrahim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189711_bb1060","doi-asserted-by":"crossref","first-page":"45682","DOI":"10.1038\/srep45682","article-title":"Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20(+) B-cell lymphoma","volume":"7","author":"Nevala","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189711_bb1065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-18-0577","article-title":"Modeling dose and schedule effects of AZD2811 nanoparticles targeting Aurora B kinase for treatment of diffuse large B-cell lymphoma","volume":"18","author":"Floc\u2019h","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189711_bb1070","doi-asserted-by":"crossref","DOI":"10.3390\/cells14171334","article-title":"Doxorubicin-loaded nanoparticle treatment enhances diffuse large B-cell lymphoma cell death","volume":"14","author":"Abd-Elrahman","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189711_bb1075","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/IJN.S289443","article-title":"Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives","author":"Edis","year":"2021","journal-title":"Int. J. Nanomedicine"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189711_bb1080","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00277-024-05880-z","article-title":"Advances in biology, diagnosis and treatment of DLBCL","volume":"103","author":"Shi","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbcan.2026.189711_bb1085","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0959-8049(22)00910-8","article-title":"New patient derived lymphoma xenograft (PDX) panel for drug development, immuno-oncology and translational research","volume":"174","author":"Brzezicha","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189711_bb1090","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/biom15060802","article-title":"Biological nanocarriers in cancer therapy: cutting edge innovations in precision drug delivery","volume":"15","author":"Ganpisetti","year":"2025","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189711_bb1095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00432-025-06172-3","article-title":"18F-FDG PET radiomics score construction by automatic machine learning for treatment response prediction in elderly patients with diffuse large B-cell lymphoma: a multicenter study","volume":"151","author":"Zhao","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:29:28Z","timestamp":1789644568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":219,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0304419X26001836"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189711","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicine-based strategies to counter chemoresistance in diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189711"}}